SA04250159B1 - مركبات benzo 4 5 thieno 2 3 d pyrimidin 4 onesواستعمالها في العلاج - Google Patents

مركبات benzo 4 5 thieno 2 3 d pyrimidin 4 onesواستعمالها في العلاج Download PDF

Info

Publication number
SA04250159B1
SA04250159B1 SA4250159A SA04250159A SA04250159B1 SA 04250159 B1 SA04250159 B1 SA 04250159B1 SA 4250159 A SA4250159 A SA 4250159A SA 04250159 A SA04250159 A SA 04250159A SA 04250159 B1 SA04250159 B1 SA 04250159B1
Authority
SA
Saudi Arabia
Prior art keywords
alkyl
aryl
group
carbon atom
compound
Prior art date
Application number
SA4250159A
Other languages
Arabic (ar)
English (en)
Inventor
لينا هيرفيلا
باسي كوسكيميز
نينا انماريا سالمينين
مارك جونسون
Original Assignee
سولفاي فارماسيتيكالز بي . في
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by سولفاي فارماسيتيكالز بي . في filed Critical سولفاي فارماسيتيكالز بي . في
Publication of SA04250159B1 publication Critical patent/SA04250159B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/08Antiseborrheics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Joining Of Glass To Other Materials (AREA)
SA4250159A 2003-06-10 2004-06-12 مركبات benzo 4 5 thieno 2 3 d pyrimidin 4 onesواستعمالها في العلاج SA04250159B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47704703P 2003-06-10 2003-06-10

Publications (1)

Publication Number Publication Date
SA04250159B1 true SA04250159B1 (ar) 2008-06-21

Family

ID=34421462

Family Applications (1)

Application Number Title Priority Date Filing Date
SA4250159A SA04250159B1 (ar) 2003-06-10 2004-06-12 مركبات benzo 4 5 thieno 2 3 d pyrimidin 4 onesواستعمالها في العلاج

Country Status (24)

Country Link
US (1) US7465739B2 (enExample)
EP (1) EP1635839B1 (enExample)
JP (1) JP4605800B2 (enExample)
KR (1) KR20060054189A (enExample)
CN (1) CN1791412A (enExample)
AR (1) AR044650A1 (enExample)
AT (1) ATE479437T1 (enExample)
AU (1) AU2004277311B8 (enExample)
BR (1) BRPI0411295A (enExample)
CA (1) CA2527617A1 (enExample)
DE (1) DE602004028934D1 (enExample)
DK (1) DK1635839T3 (enExample)
ES (2) ES2352552T3 (enExample)
IL (1) IL172316A0 (enExample)
MX (1) MXPA05012745A (enExample)
NO (1) NO20060123L (enExample)
PL (1) PL1635839T3 (enExample)
PT (1) PT1635839E (enExample)
RU (1) RU2412190C2 (enExample)
SA (1) SA04250159B1 (enExample)
SI (1) SI1635839T1 (enExample)
TW (1) TWI349551B (enExample)
WO (1) WO2005032527A2 (enExample)
ZA (1) ZA200508296B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
WO2005108376A1 (en) * 2004-05-06 2005-11-17 Smithkline Beecham Corporation Calcilytic compounds
WO2006044826A2 (en) * 2004-10-20 2006-04-27 Compass Pharmaceuticals Llc Thiophens and their use as anti-tumor agents
BRPI0419229A (pt) * 2004-12-13 2007-12-18 Solvay Pharm Gmbh derivados de tiofenopirimidinona substituìdos como inibidores de 17beta-hidroxiesteróide-desidrogenase, uso e composição farmacêutica
FR2904000A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
FR2904318B1 (fr) * 2006-07-27 2011-02-25 Scras Derives de pyrimidinone et leur utilisation comme medicament
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
DE102007040243A1 (de) * 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
EP2381775A4 (en) * 2008-12-23 2012-08-15 Harvard College INHIBITORS OF NECROPTOSIS OF SMALL MOLECULAR SIZE
EP2609089A1 (en) 2010-08-27 2013-07-03 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2012119605A1 (en) * 2011-03-10 2012-09-13 Akar Yahya Ahmed Abdellhafeez Salem New disperse dye with potent anticancer activity
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
AR096728A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados de estratrieno-tiazol terapéuticamente activos
AR096729A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados terapéuticamente activos de estratien-tiazol
JP6456373B2 (ja) 2013-06-25 2019-01-23 フォレンド ファーマ リミテッド 17β−ヒドロキシステロイドデヒドロゲナーゼ タイプ1の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
EP3089969A2 (en) 2014-01-03 2016-11-09 Elexopharm GmbH Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
GB201419102D0 (en) * 2014-10-27 2014-12-10 Imp Innovations Ltd Novel compounds
WO2016102775A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd PRODRUGS OF 17β-HSD1 -INHIBITORS
JP6523461B2 (ja) 2014-12-23 2019-06-05 フォレンド ファーマ リミテッド 17β−HSD1−阻害剤のプロドラッグ
CA3003930A1 (en) * 2015-11-04 2017-05-11 Simon Fraser University Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
DK3634975T3 (da) 2017-06-08 2024-05-27 Organon R&D Finland Ltd 17-oximer af 15.beta.-[3-propanamido]-substituerede estra-1,3,5(10)-trien-17-oner til anvendelse i inhibition af 17.beta.-hydroxysteroid-dehydrogenaser
CN109503572B (zh) * 2017-09-15 2021-10-08 上海交通大学 一种合成吲哚喹啉类化合物的方法
CA3122049C (en) 2018-12-05 2023-10-17 Forendo Pharma Ltd Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1
AU2023260728A1 (en) * 2022-04-28 2024-10-10 Enanta Pharmaceuticals, Inc. Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors
US20250154163A1 (en) * 2023-10-26 2025-05-15 Enanta Pharmaceuticals, Inc. Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4742271B1 (enExample) * 1968-06-20 1972-10-25
US3775027A (en) 1971-10-01 1973-11-27 Gray Manuf Co Inc Two-speed pump
JPS62132884A (ja) 1985-12-05 1987-06-16 Mitsubishi Chem Ind Ltd 2−ベンジルチエノ〔2,3−d〕ピリミジン−4(3H)−オン誘導体
WO1989008113A1 (en) 1988-03-02 1989-09-08 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-DIHYDROTHIENO[2,3-d]PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL APPLICATION THEREOF
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
JP3783810B2 (ja) 1997-01-14 2006-06-07 第一製薬株式会社 新規ベンゾフラノン誘導体及びその製造方法
JPH10273467A (ja) 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
AU9001698A (en) 1997-09-11 1999-03-29 Snow Brand Milk Products Co., Ltd. Remedies for hormone-dependent diseases
TR200002784T2 (tr) 1998-03-11 2000-12-21 Endorecherche, Inc Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
US6291505B1 (en) 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
AU2001296961A1 (en) 2000-09-29 2002-04-08 Bayer Pharmaceuticals Corporation 17-beta-hydroxysteroid dehydrogenase-ii inhibitors
WO2003017974A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
ES2276950T3 (es) 2001-09-06 2007-07-01 Schering Corporation Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades dependientes de androgenos.
US6750248B2 (en) 2001-11-09 2004-06-15 National University Of Singapore Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof

Also Published As

Publication number Publication date
US7465739B2 (en) 2008-12-16
RU2006100033A (ru) 2007-07-20
MXPA05012745A (es) 2006-05-17
TW200509937A (en) 2005-03-16
AU2004277311B8 (en) 2010-05-27
WO2005032527A3 (en) 2005-08-04
AU2004277311A1 (en) 2005-04-14
TWI349551B (en) 2011-10-01
WO2005032527B1 (en) 2005-09-22
ZA200508296B (en) 2007-01-31
AR044650A1 (es) 2005-09-21
EP1635839B1 (en) 2010-09-01
AU2004277311B2 (en) 2010-04-29
KR20060054189A (ko) 2006-05-22
PT1635839E (pt) 2010-10-12
CN1791412A (zh) 2006-06-21
ATE479437T1 (de) 2010-09-15
BRPI0411295A (pt) 2006-08-01
NO20060123L (no) 2006-03-09
EP1635839A2 (en) 2006-03-22
ES2352552T3 (es) 2011-02-21
DK1635839T3 (da) 2011-01-03
PL1635839T3 (pl) 2011-02-28
RU2412190C2 (ru) 2011-02-20
DE602004028934D1 (de) 2010-10-14
IL172316A0 (en) 2011-08-01
JP4605800B2 (ja) 2011-01-05
US20050038053A1 (en) 2005-02-17
CA2527617A1 (en) 2005-04-14
JP2006527226A (ja) 2006-11-30
SI1635839T1 (sl) 2010-12-31
ES2352554T3 (es) 2011-02-21
WO2005032527A2 (en) 2005-04-14

Similar Documents

Publication Publication Date Title
SA04250159B1 (ar) مركبات benzo 4 5 thieno 2 3 d pyrimidin 4 onesواستعمالها في العلاج
JP7014765B2 (ja) ピラゾロ化合物及びその使用
CN102333779B (zh) 苯并吡喃和苯并氧杂*pi3k抑制剂化合物和使用方法
SA04250158B1 (ar) استعمال مركبات ثيوفين بيرميدينو thiophene pyrimidinone في معالج و /أو منع الأمراض الهرمونية الستيرويدية steroid hormone
KR20210003764A (ko) 전사 활성화 단백질의 이미다조피페라진 억제제
BRPI0713216A2 (pt) inibiadores heterocìclos fundidos da d-aminoácido oxidase
TW200800894A (en) Carboxyamine compounds and methods of use thereof
TW202332439A (zh) p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途
WO2016196955A1 (en) Inhibitors of RAD52 Recombination Protein and Methods Using Same
US7524853B2 (en) Compounds and their use in therapy
AU2004325692B2 (en) Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase
JP2023544173A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
HK1113676A (en) NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE
JP2023544732A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
MXPA05012871A (en) Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors
KR20070106994A (ko) 17β­하이드록시스테로이드 탈수소효소의 저해제로서신규한 치환된 티오펜피리미디논 유도체
HK1087331B (en) Thiophenepyrimidinones as 17-beta-hydroxysteroid dehydrogenase inhibitors
TW200906833A (en) Fused heterocyclic inhibitors of D-amino acid oxidase